Brief: Alphamab Oncology Says Phase I/II Clinical Trial Of JSKN033 Approved In Australia
08/12/2023 09:07
Dec 8 (Reuters) - Alphamab Oncology 9966.HK :
* PHASE I/II CLINICAL TRIAL OF JSKN033 APPROVED BY BELLBERRY
HUMAN
RESEARCH ETHICS COMMITTEE IN AUSTRALIA
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)